المؤلفون: Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Garralda E; Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Hospital, Barcelona, Spain., Schöffski P; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium., Hong DS; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas and MD Anderson Cancer Center, Houston, TX, USA., Siu LL; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada., Martin M; Gregorio Marañón Hospital, Universidad Complutense, Madrid, Spain., Maur M; Oncology and Haematology Department, Università degli Studi di Modena e Reggio Emilia, Emilia-Romagna, Italy., Hui R; Department of Medical Oncology, Westmead Hospital and the University of Sydney, Sydney, Australia., Soo RA; Department of Haematology-Oncology, National University Cancer Institute, Singapore., Chiu J; Department of Medicine, Queen Mary Hospital, Hong Kong, China., Zhang T; Department of Medicine, Duke Cancer Institute, Durham, NC, USA., Ma B; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Kyi C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tan DS; National Cancer Centre, Singapore and Duke-NUS Medical School, Singapore., Cassier PA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Sarantopoulos J; Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA., Weickhardt A; Medical Oncology Dept, Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Victoria, Australia., Carvajal RD; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA., Spratlin J; Cross Cancer Institute, University of Alberta, Edmonton, Canada., Esaki T; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Rolland F; Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Centre René Gauducheau, Nantes, France., Akerley W; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Deschler-Baier B; Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany., Rispoli L; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Samant TS; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Chowdhury NR; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Gusenleitner D; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Kwak EL; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Askoxylakis V; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., De Braud F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy and Oncology and Hemato-oncology Department, University of Milan, Milan, Italy.

المصدر: Oncoimmunology [Oncoimmunology] 2023 Dec 20; Vol. 13 (1), pp. 2290787. Date of Electronic Publication: 2023 Dec 20 (Print Publication: 2024).

نوع المنشور: Multicenter Study; Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Melanoma*/drug therapy , Melanoma*/genetics , Carcinoma, Renal Cell*/drug therapy , Lung Neoplasms*/drug therapy , Kidney Neoplasms*/drug therapy , Exanthema*/chemically induced , Exanthema*/drug therapy, Humans ; Antibodies, Monoclonal/therapeutic use ; Immune Checkpoint Inhibitors/therapeutic use ; Biomarkers ; Fatigue/chemically induced ; Fatigue/drug therapy

المؤلفون: Sánchez-García A; Endocrinology Division, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José E. González', Monterrey, Mexico., Támez-Guerra R; Laboratorio de Inmunología y Virología, Departamento de Microbiología e Inmunología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico., González-Saldivar G; Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Calle Dr. Eduardo Aguirre Pequeño s/n Edificio CRIDS, Monterrey, Mexico., Rodríguez-Gutiérrez R; Endocrinology Division, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José E. González', Monterrey, Mexico.; Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Calle Dr. Eduardo Aguirre Pequeño s/n Edificio CRIDS, Monterrey, Mexico.; Knowledge and Evaluation Research Unit in Endocrinology, Mayo Clinic, Rochester, MN, USA., Ramírez-García LA; Endocrinology Division, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José E. González', Monterrey, Mexico., Barrera FJ; Endocrinology Division, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José E. González', Monterrey, Mexico., González-González JG; Endocrinology Division, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario 'Dr. José E. González', Monterrey, Mexico.; Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Calle Dr. Eduardo Aguirre Pequeño s/n Edificio CRIDS, Monterrey, Mexico.

المصدر: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 15; Vol. 19 (3), pp. 2271760. Date of Electronic Publication: 2023 Nov 08.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19*/prevention & control , Exanthema*, Adult ; Humans ; Immunization, Secondary ; BCG Vaccine ; Pandemics/prevention & control

المؤلفون: Tomita N; Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan., Terada-Hirashima J; Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan., Uemura Y; Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan., Shimizu Y; Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan., Iwasaki H; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan., Yano R; Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan., Suzuki T; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan., Saito S; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan., Okumura N; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan., Sugiura W; Centre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo, Japan., Ohmagari N; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan., Ujiie M; Disease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo, Japan.

المصدر: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Aug 01; Vol. 19 (2), pp. 2242219.

نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

مواضيع طبية MeSH: Exanthema* , Post-Exposure Prophylaxis* , Smallpox Vaccine*/adverse effects , Mpox (monkeypox)*/prevention & control, Humans ; Antigens, Viral ; Cell Culture Techniques

المؤلفون: Zhang Q; University of Lanzhou of the First School of Clinical Medicine, Lanzhou, China., Xie P; Department of Radiation Oncology, The First Hospital of Lanzhou University, Lanzhou, China., Hou X; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China., Zhao C; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China., Duan L; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China., Qiao H; Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China.; School of Life Sciences, Lanzhou University, Lanzhou, China.

المصدر: Journal of chemotherapy (Florence, Italy) [J Chemother] 2024 Jul; Vol. 36 (4), pp. 334-342. Date of Electronic Publication: 2023 Nov 01.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 8907348 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1973-9478 (Electronic) Linking ISSN: 1120009X NLM ISO Abbreviation: J Chemother Subsets: MEDLINE

مواضيع طبية MeSH: Acrylamides*/therapeutic use , Acrylamides*/adverse effects , Aniline Compounds*/therapeutic use , Aniline Compounds*/adverse effects , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , ErbB Receptors*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/adverse effects, Humans ; Male ; Middle Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Exanthema/chemically induced ; Exons ; Indoles ; Pyrimidines ; Sequence Deletion

المؤلفون: Kuo AM; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hassoun H; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shah U; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gordon A; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hollmann TJ; Dermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Landau HJ; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lezcano C; Dermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mailankody S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tan CC; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lesokhin AM; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Markova A; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2022 Sep; Vol. 63 (9), pp. 2233-2237. Date of Electronic Publication: 2022 May 09.

نوع المنشور: Letter; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Exanthema*/drug therapy , Exanthema*/etiology , Multiple Myeloma*/complications , Multiple Myeloma*/drug therapy, Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/therapeutic use ; Humans ; Lenalidomide/adverse effects

المؤلفون: Sollena P; Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Cappilli S; Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy., Federico F; Department of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Schinzari G; Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Tortora G; Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Peris K; Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy.

المصدر: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 May 31; Vol. 18 (3), pp. 1889449. Date of Electronic Publication: 2021 Mar 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal*/adverse effects , Antineoplastic Agents, Immunological*/adverse effects , Exanthema*/chemically induced , Immunotherapy*/adverse effects , Melanoma*/drug therapy, CTLA-4 Antigen/antagonists & inhibitors ; Humans

المؤلفون: Abdayem P; Department of Cancer Medicine, Thoracic Oncology Unit, Gustave Roussy Cancer Campus, Villejuif, France., Planchard D; Department of Cancer Medicine, Thoracic Oncology Unit, Gustave Roussy Cancer Campus, Villejuif, France.

المصدر: Expert opinion on drug safety [Expert Opin Drug Saf] 2021 Jun; Vol. 20 (6), pp. 651-667. Date of Electronic Publication: 2021 Mar 25.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung/*drug therapy , Exanthema/*chemically induced , Immune Checkpoint Inhibitors/*adverse effects , Lung Neoplasms/*drug therapy , Pneumonia/*chemically induced , Thyroiditis/*chemically induced, Adrenal Cortex Hormones/therapeutic use ; COVID-19/diagnosis ; Diagnosis, Differential ; Disease Progression ; Drug-Related Side Effects and Adverse Reactions ; Exanthema/drug therapy ; Exanthema/immunology ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Pneumonia/diagnosis ; Pneumonia/drug therapy ; Pneumonia/immunology ; Practice Guidelines as Topic ; SARS-CoV-2 ; Thyroiditis/drug therapy ; Thyroiditis/immunology

المؤلفون: Sugi T; Department of Pharmacy, Eiju General Hospital, Tokyo, Japan.; Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan., Nishigami Y; Department of Pharmacy, Eiju General Hospital, Tokyo, Japan., Saigo H; Department of Pharmacy, Eiju General Hospital, Tokyo, Japan., Hanai H; Department of Pharmacy, Eiju General Hospital, Tokyo, Japan., Takabatake K; Department of Pharmacy, Eiju General Hospital, Tokyo, Japan., Mita M; Department of Cardiovascular Pharmacology, Education and Research Unit for Comprehensive Clinical Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan., Ohara S; Department of Hematology, Eiju General Hospital, Tokyo, Japan., Ide S; Department of Hematology, Eiju General Hospital, Tokyo, Japan., Uchida T; Department of Hematology, Eiju General Hospital, Tokyo, Japan., Inoue M; Department of Hematology, Eiju General Hospital, Tokyo, Japan., Hagihara M; Department of Hematology, Eiju General Hospital, Tokyo, Japan.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2021 Jun; Vol. 62 (6), pp. 1405-1410. Date of Electronic Publication: 2021 Jan 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Exanthema*/chemically induced , Exanthema*/diagnosis , Exanthema*/epidemiology , Multiple Myeloma*/drug therapy, Aged ; Antineoplastic Combined Chemotherapy Protocols ; Dexamethasone/therapeutic use ; Humans ; Lenalidomide/adverse effects ; Retrospective Studies ; Risk Factors

المؤلفون: Yau P; Department of Pharmacy, Tom Baker Cancer Center, Calgary, AB, Canada., Jimenez-Zepeda VH; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada., Bailey K; Department of Pharmacy, Tom Baker Cancer Center, Calgary, AB, Canada., Duggan P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada., Tay J; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada., Bahlis NJ; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada., Neri P; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada., McCulloch S; Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (13), pp. 3199-3203. Date of Electronic Publication: 2019 Jun 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Desensitization, Immunologic/*methods , Drug Eruptions/*therapy , Exanthema/*therapy , Hypersensitivity, Delayed/*therapy , Immunologic Factors/*administration & dosage , Lenalidomide/*administration & dosage , Multiple Myeloma/*drug therapy, Aged ; Aged, 80 and over ; Cancer Care Facilities ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Eruptions/etiology ; Exanthema/chemically induced ; Exanthema/immunology ; Female ; Humans ; Hypersensitivity, Delayed/chemically induced ; Hypersensitivity, Delayed/immunology ; Immunologic Factors/adverse effects ; Immunologic Factors/immunology ; Lenalidomide/adverse effects ; Lenalidomide/immunology ; Male ; Middle Aged ; Multiple Myeloma/immunology ; Outpatient Clinics, Hospital ; Skin/drug effects ; Skin/immunology ; Time Factors ; Treatment Outcome

المؤلفون: Dote S; Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan.; Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan., Ito K; Department of Pharmacy, Fujita Health University Hospital, Aichi, Japan., Itakura S; Department of Pharmacy, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan., Yasu T; Department of Pharmacy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Hira D; Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan.; College of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan., Noda S; Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan., Yamada S; Department of Pharmacy, Fujita Health University Hospital, Aichi, Japan., Kobayashi Y; Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan., Terada T; Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2019 Dec; Vol. 60 (12), pp. 2975-2981. Date of Electronic Publication: 2019 May 03.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Bortezomib/*adverse effects , Exanthema/*epidemiology , Exanthema/*etiology , Lenalidomide/*adverse effects , Multiple Myeloma/*complications , Multiple Myeloma/*epidemiology, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/therapeutic use ; Cohort Studies ; Disease Susceptibility ; Eosinophilia/diagnosis ; Eosinophilia/epidemiology ; Eosinophilia/etiology ; Exanthema/diagnosis ; Female ; Humans ; Incidence ; Lenalidomide/therapeutic use ; Male ; Multiple Myeloma/drug therapy ; Propensity Score